Mochida Pharmaceutical Co., Ltd.

As of March 31, 2026, Mochida Pharmaceutical Co., Ltd. carries a market capitalization of 659.36M, placing it among publicly traded companies globally. Its enterprise value stands at 544.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mochida Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 9, 2026.

As of March 31, 2026, Mochida Pharmaceutical Co., Ltd. has 35.45M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Mochida Pharmaceutical Co., Ltd. maintains a current ratio of 4.29, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Mochida Pharmaceutical Co., Ltd.'s stock has gained approximately 6.43% over the past 52 weeks. The 50-day moving average sits at 17.51, while the 200-day moving average is 18.08.

As of March 31, 2026, Mochida Pharmaceutical Co., Ltd. holds 169.31M in cash and equivalents against 54.52M in total debt, resulting in a net debt position of -98.48M. Total book value stands at 765.01M, with working capital of 497.67M providing operational flexibility.

Mochida Pharmaceutical Co., Ltd.'s most recent stock split took place on March 27, 2019 with a 1:2 split ratio.